Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *wnrz4*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2MjExNDM2OS4yODMuMS4xNjYyMTE0NjczLjAuMC4w&_ga=2.171959712.162264177.1661851705-1303344198.1644848097?utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_mcmurray

Prof John McMurray (University of Glasgow, UK) joined us to discuss the finding of the PERSPECTIVE trial (NCT02884206).
The trial assessed whether the angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan (Novartis) has any negative impact on cognitive function in people who have heart failure with preserved ejection fraction (HFpEF) when compared with HFpEF patients taking valsartan alone.

Questions
1. What is the background for the PERSPECTIVE trial?
2. What was the design and outcomes?
3. What were the challenges?

Recorded at ESC 22, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "ESC 2022: PERSPECTIVE: Sacubitril/Valsartan & Cognitive Function in HFmrEF & HFpEF" передвинте ползунок вправо